Jefferies Remains Sidelined on Gilead Sciences (GILD) Following 2Q - PT to $93

Gilead Sciences (GILD) PT Bumped to $98 at BMO Capital Posts Q2, Remains Sidelined

BMO Capital analyst Ian Somaiya bumped his price target on Gilead Sciences (NASDAQ: GILD) to $98.00 (from $97.00) but maintained a Market Perform rating following Q2 results after the close.

Somaiya commented, "Gilead's 2Q16 results support our below-consensus view of the company's HCV... More

Gilead Sciences (GILD) PT Lowered to $108 at Piper Jaffray

Piper Jaffray analyst Joshua Schimmer lowered his price target on Gilead Sciences (NASDAQ: GILD) to $108.00 (from $114.00) following results and lowered guidance but maintained an Overweight rating.

Schimmer commented, "After the close, GILD reported 2Q results, lowering its revenue and raising its opex guidance... More

Gilead Sciences (GILD) PT Trimmed to $115 at Credit Suisse

Credit Suisse analyst Alethia Young lowered estimates and her price target on Gilead Sciences (NASDAQ: GILD) to $115.00 (from $120.00) following results but maintained a Outperform rating.

Young commented, "Harvoni was the focus heading into the quarter; it missed consensus and guidance was lowered (likely due to HCV). Total revenues... More

Needham & Company Downgrades Gilead Sciences (GILD) to Hold

Needham & Company downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.

Analyst Alan Carr commented, "Gilead reported 2Q16 financial results yesterday. Product sales of $7.65B were consistent w/ our $7.71B and consensus $7.77B expectations. WW Harvoni and Sovaldi sales were $2.56B and $1.36B... More

Gilead Sciences (GILD): Lower Revenue Guidance Highlights Concerns - Baird

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) but is incrementally more cautious after earnings. Though Hep C sales met expectations, management didn't show as much confidence in a stabilization as they have in the... More

After-Hours Movers 7/25: (CLGX) (TXN) (SGY) Higher; (MSTX) (CRME) (SANM) Lower

Mast Therapeutics (NYSE: MSTX) 22.6% LOWER; On July 25, 2016, Mast Therapeutics provided guidance on the anticipated timing for announcement of top-line data from the EPIC study. The Company expects to report top-line data in September 2016. The Company believes that the additional time needed to lock the study database does not reflect on the quality or integrity of the results or conduct of the study. Rather, validation of the multitude of data points and quality assurance/quality control procedures have taken longer than the Company previously anticipated. Allocation of key resources to the... More

Gilead Sciences (GILD) Declares $0.47 Quarterly Dividend; 2.1% Yield

Gilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.47 per share, or $1.88 annualized.

The dividend will be payable on September 29, 2016, to stockholders of record on September 16, 2016, with an ex-dividend date of September 14, 2016.

The annual yield on the dividend is 2.1... More

Gilead Sciences (GILD) Tops Q2 EPS by 6c

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $3.08, $0.06 better than the analyst estimate of $3.02. Revenue for the quarter came in at $7.78 billion versus the consensus estimate of $7.79 billion.

otal product sales for the second quarter of 2016 were $7.7 billion compared to $8.1 billion for the same period in 2015. Product sales for the second quarter of 2016 were $4.9... More

Wall St. declines as earnings take center stage

By Noel Randewich

(Reuters) - U.S. stocks receded from record highs on Monday as oil weighed on energy shares and investors awaited an avalanche of quarterly reports.

Shares fell almost across the board, with energy stocks leading declines across 10 S&P 500 sectors and the consumer discretionary sector the lone gainer, helped by a 1.84-percent gain in Target (NYSE: TGT).

The negative start to the week, which includes earnings from 190 S&P 500 companies as well as a Federal Reserve policy meeting, put the brakes on a 9-percent rally that started on June 27.... More

Gilead Sciences (GILD) July weekly volatility increases into Q2 and outlook

Gilead Sciences (NASDAQ: GILD) July weekly call option implied volatility is at 49, August is at 31; compared to its 52-week range of 22 to 49 into the expected release of Q2 results on July 25.

Trading Radar for 7/25: Sprint (S), Danaher (DHR), Texas Instruments (TXN), Las Vegas Sands (LVS), Kimberly-Clark (KMB) Report

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

Bank Of Hawaii Corp. (NYSE: BOH) - consensus EPS $0.93
Bank Of Marin Bancorp (Nasdaq: BMRC) - no Street consensus
Danaher (NYSE: DHR) - consensus EPS $1.22
Eagle Materials (NYSE: EXP) - consensus EPS $0.86
Euronet Worldwide (Nasdaq: EEFT) - no Street... More

Gilead (GILD) Receives Updated CHMP Recommendations on Zydelig as CLL, Follicular Lymphoma Treatment

The CHMP (EMAs Committee for Medicinal Products for Human Use) has confirmed that the benefits of Gilead's (Nasdaq: GILD) Zydelig (idelalisib) in the treatment of the blood cancers chronic lymphocytic leukaemia (CLL) and follicular lymphoma outweigh the risk of side effects. However, following a review it has updated recommendations to minimise the risk of serious infections in patients treated with the medicine.

All patients treated with Zydelig should be given... More

Gilead Sciences (GILD) Receives Positive CHMP Opinion on Updated Truvada Marketing Terms

On 21 July 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Truvada. The marketing authorisation holder for this medicinal product is Gilead Sciences International Ltd. (Nasdaq: GILD).

The CHMP adopted a new indication as... More